Search
for
Sort by
Research 721–750 of 1000+
- Long-Term Suppression of Testosterone After Treatment with a Gonadotropin-Releasing Hormone Agonist in a Woman with a Presumed Testosterone Secreting Ovarian Tumor
- Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy
- A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism.
- Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study.
- (PNM-35) Recurrent priapism in a sickle cell disease patient treated with gonadotropin-releasing hormone (GnRH) agonists drugs: a case report
- A Novel Nomogram for Predicting Gonadotropin-Releasing Hormone Analogue Treatment Outcome in Girls with Idiopathic Central Precocious Puberty
- Dienogest versus gonadotropin-releasing hormone analogues for the clinical treatment of endometriosis: an updated meta-analysis
- Puberty in Boys: Correlation of Plasma Levels of Gonadotropins (LH, FSH), Androgens (Testosterone, Androstenedione, Dehydroepiandrosterone and Its Sulfate), Estrogens (Estrone and Estradiol) and Progestins (Progesterone and 17-Hydroxyprogesterone)
- Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission
- Utilisation of gonadotrophin-releasing hormone (GnRH) analogue to differentiate ovarian from adrenal hyperandrogenism in postmenopausal women
- Effect of the gonadotrophin releasing hormone analogue, goserelin, and oestradiol replacement on sebum excretion rates and hair size in mildly hirsute women
- DIAGNOSTIC AND THERAPEUTIC UTILITY OF GONADOTROPHIN-RELEASING HORMONE AGONIST IN POSTMENOPAUSAL HYPERANDROGENISM OF OVARIAN ORIGIN
- Role of Environmental Factors and Gonadotoxin Exposure in Unexplained Male Infertility
- Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men.
- Telogen Effluvium Secondary to Weight Loss and Therapy With Chorionic Gonadotropin
- Hair Loss After Therapy with Chorionic Gonadotropin
- Luteinizing Hormone and Human Chorionic Gonadotropin Decrease Type 2 5α-Reductase and Androgen Receptor Protein Levels in Women’s Skin
- Ovarian and Adrenal Androgens and Their Link to High Human Chorionic Gonadotropin Levels: A Prospective Controlled Study
- Re: Clomiphene Citrate and Human Chorionic Gonadotropin are Both Effective in Restoring Testosterone in Hypogonadism: A Short-Course Randomized Study
- Alopecia Areata: Pituitary Function Assessed by Assay of Pituitary Gonadotropin in Urine11From the Section of Dermatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota. The Mayo Foundation, Rochester, Minnesota, is a part of the Graduate School of the University of Minnesota.
- Differential Suppression of Testosterone and Estradiol in Hirsute Women With the Superactive Gonadotropin-Releasing Hormone Agonist Leuprolide*
- Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men
- Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline
- Epidemiology, diagnosis, and management of polycystic ovary syndrome
- Cross‐Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short‐Time Follow‐Up: Results from the European Network for the Investigation of Gender Incongruence
- Clinical Management of Youth with Gender Dysphoria in Vancouver
- Management of Transgenderism
- Intratesticular Control Of Steroidogenesis
- Clinical and endocrine effects of finasteride, a 5α-reductase inhibitor, in women with idiopathic hirsutism
- Interventions for hirsutism (excluding laser and photoepilation therapy alone)